Capecitabine plus usual treatment for high-risk HER2 breast cancer
Treatments studied
Part of Cancer, Skin clinical trials.
This trial looks at whether adding a chemotherapy medicine called capecitabine (taken in smaller, regular doses) to the standard after-surgery (adjuvant) treatment can lower the chance of cancer coming back in people with early-stage, high-risk HER2-positive breast cancer. It targets patients who still had cancer left after earlier treatment or who had higher-risk tumor features.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have early-stage, operable HER2-positive invasive breast cancer
- Your surgery after treatment must have removed all visible cancer in the breast and lymph nodes
- You are considered “high risk,” such as cancer still remaining after neoadjuvant therapy, positive lymph nodes, or tumor larger than 2 cm
- If you had neoadjuvant therapy, you completed enough chemo and HER2 treatment weeks before surgery (at least 6 cycles, with specific trastuzumab and taxane timing requirements)
- Your blood counts, liver, and kidney tests are adequate before starting (including low enough clotting and inflammation blood markers)
- Your heart pumping function is strong enough (LVEF meets the trial threshold) and you can safely take HER2-related treatment
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This Phase 3 study tests whether adding capecitabine (a chemotherapy pill) after breast cancer surgery can lower the chance the cancer comes back. It targets people with hormone-receptor–positive and HER2-negative breast cancer who are considered “high risk.”
This trial tests if adding a chemotherapy drug called capecitabine to the combination of dalpiciclib and hormone therapy works better than dalpiciclib and hormone therapy alone for advanced breast cancer that is hormone receptor-positive and HER2-negative. It is for people who have not had these treatments before.
This trial studies whether a low-dose “metronomic” chemotherapy medicine (capecitabine) added to standard hormone therapy can reduce breast cancer coming back. It is for people with hormone-receptor–positive, HER2-negative breast cancer after surgery and chemo.
This trial tests whether a chemotherapy pill called capecitabine can help people with low-risk triple negative breast cancer after surgery. It is for patients with stage I disease who have certain features that suggest a lower chance of recurrence.
This Phase 1b/2 trial tests how safe and how well capecitabine combined with niraparib works for people with HER2-negative, hormone-resistant advanced breast cancer. It may help by slowing tumor growth after standard chemotherapy options have been tried.
This trial tests if adding a new oral targeted therapy (elacestrant) to standard chemotherapy (capecitabine) works better than chemotherapy alone for people with a specific type of advanced breast cancer that is hormone-sensitive (ER-positive) and has stopped responding to hormone therapy.
Hear when a new Breast cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.